Jiangxi Jemincare Pharmaceutical

Jemincare is a leading private Chinese pharmaceutical company founded in 1999 and headquartered in Nanchang. The company has evolved from a traditional Chinese medicine provider into a modern biopharmaceutical powerhouse with a robust pipeline of innovative small molecules and biologics. Jemincare operates a major R&D center in Shanghai, focusing on therapeutic areas including oncology, nephrology, cardiovascular, and metabolic diseases. The company gained international prominence through significant out-licensing agreements, such as the $600 million deal with Genentech for an androgen receptor degrader and a global license agreement with AstraZeneca for a Claudin 18.2 antibody-drug conjugate. With extensive manufacturing capabilities and a large commercial footprint in China, Jemincare is a key player in the transition of the Chinese pharma industry toward global innovation.